Clinical trial
Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
NCT07465666 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- August 31, 2027
- Enrollment
- 500 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.